紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床观察  

Clinical Observation on TP in Patients with Treatment of Advanced Non-small Cell Lung Carcinoma

作　　者：崔莉[1] 裴福恩[1] 韩仰光[1] 

机构地区：[1]江苏大学附属人民医院呼吸科,江苏镇江212002

出　　处：《江苏大学学报（医学版）》2005年第3期227-228,231,共3页Journal of Jiangsu University：Medicine Edition

摘　　要：目的:观察抗肿瘤药物紫杉醇(TAXOL)、顺铂(DDP)组成的TP方案和丝裂霉素(MMC)、长春地辛(VDS)和顺铂(DDP)组成的MVP方案治疗晚期非小细胞肺癌的近期疗效和毒副反应。方法:65例入院化疗的非小细胞肺癌患者随机分为两组,分别采用TP方案和MVP方案化疗,28天为一周期,重复3个周期。结果:两组有效率,TP组45.5%,MVP组34.3%,经比较两组有效率无显著性差异(P>0.05);毒副反应主要为骨髓抑制,MVP组较TP组为明显(P<0.05);其次为胃肠道反应和脱发,二组相似。结论:TP方案和MVP方案是治疗晚期非小细胞肺癌的有效方案。MVP方案骨髓抑制较TP方案严重,因此治疗晚期非小细胞肺癌用TP方案较为理想。Objective: To observe the combination chemotherapy efficacy and toxicity of the anti-tumor drug taxol、cisplation(TP)and mitomycin-c,vindesine and cisplation(MVP) treated advanced non small cell lung carcinoma (NSCLC).Methods: Sixty-five patients with NSCLC were randomly divided into two groups, and were treated by TP regimen and MVP regimen respectively.Results: Response rate(RR) in TP group was 45.5%,and RR in MVP group was 34.3%.There were no difference between two groups in response rate( P>0.05);The major toxicity was marrow suppression, and myelosuppression of MVP group was more serious than that in TP group( P<0.05).The other toxicities were nausea and alopecia. Conclusion: The TP regimen was a better regimen for advanced NSCLC.Its side effects could be overcome.

关 键 词：紫杉醇 顺铂 联合化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]